Dublin, Dec. 08, 2025 (GLOBE NEWSWIRE) — The “Companion Animal Pharmaceuticals Market – Global Forecast 2025-2032” has been added to ResearchAndMarkets.com’s offering.
The Companion Animal Pharmaceuticals Market, which saw a progression from USD 17.53 billion in 2024 to USD 18.85 billion in 2025, is predicted to further grow at a CAGR of 7.82%, reaching an estimated USD 32.04 billion by 2032. Transformed by escalating pet ownership and increased owner expectations, this sector has become a pivotal space for innovation. Urban living trends and dual-income households have amplified the role of pets in family structures, leading to a surge in preventative care and specialty treatment demand.
Strategic Industry Overview
The companion animal pharmaceuticals sector is driven by significant innovation factors, regulatory contexts, and emerging priorities. The regulatory landscape has evolved to support animal welfare while promoting scientific progress through intensified pharmacovigilance requirements. Increased private investment in veterinary biotech also contributes to the development of monoclonal antibodies, vaccines, and diagnostic tools.
Emerging Paradigm Shifts in Drug Development
The landscape is evolving with scientific breakthroughs and technological advancements. Biologics, precision vaccines, and recombinant interferons are redefining treatment approaches, while digital health and telemedicine enhance chronic condition management. New regulatory frameworks balance innovation with safety, emphasizing antimicrobial stewardship. Industry players aiming for competitive advantage must align R&D, regulatory strategies, and digital capacities.
Key Takeaways from This Report
- Biologics and digital integration are reshaping drug development.
- Major economic pressures and regulatory trends affect competitive strategies.
- Strategic initiatives, such as R&D partnerships and digital platforms, drive future growth.
- Understanding market dynamics is essential for identifying opportunities and mitigating risks.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 187 |
| Forecast Period | 2025 – 2032 |
| Estimated Market Value (USD) in 2025 | $18.85 Billion |
| Forecasted Market Value (USD) by 2032 | $32.04 Billion |
| Compound Annual Growth Rate | 7.8% |
| Regions Covered | Global |
Companies Featured
The companies profiled in this Companion Animal Pharmaceuticals market report include:
- Alivira Animal Health Limited
- Ashish Life Science Pvt. Ltd.
- Boehringer Ingelheim International GmbH
- Ceva Sante Animale
- Chanelle Pharma
- Dechra Pharmaceuticals PLC
- Eco Animal Health Group PLC
- Elanco Animal Health Incorporated
- Endovac Animal Health, LLC
- Hester Biosciences Limited
- Hipra Laboratories, S.A.
- Indian Immunologicals Ltd.
- Kyoritsu Seiyaku Corporation
- Meiji Group
- Merck KGaA
- Neogen Corporation
- Norbrook Laboratories Ltd.
- Orion Corporation
- Phibro Animal Health Corporation
- SkyEc Pharmaceuticals Private Limited
- Stanex Drugs and Chemicals Pvt Ltd.
- Tianjin Ringpu Biotechnology Co., Ltd.
- Veko Care
- Vetbiolix
- Virbac S.A.
- Zoetis Inc.
- Zydus Animal Health
For more information about this report visit https://www.researchandmarkets.com/r/fzl1n0
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Companion Animal Pharmaceuticals Market
